| Previous close | 21.50 |
| Open | 22.46 |
| Bid | 23.60 |
| Ask | 24.25 |
| Strike | 920.00 |
| Expiry date | 2024-08-16 |
| Day's range | 22.46 - 24.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 856 |
Investor's Business DailyEli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
Eli Lilly stock inched ahead Monday as a panel of advisors to the FDA gathered to discuss its experimental Alzheimer's treatment, donanemab.
ZacksBiogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
ZacksEli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
© 2024 Yahoo. All rights reserved.